Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Per977
1. 1438492-26-2
2. Per977
3. Per-977
4. Ciraparantag [usan]
5. Ciraparantag(per977)
6. U2r67kv65q
7. 1438492-26-2 (free Base)
8. Ciraparantag (usan)
9. N1,n1'-(piperazine-1,4-diylbis(propane-1,3-diyl))bis-l-argininamide
10. Pentanamide, N,n'-(1,4-piperazinediyldi-3,1-propanediyl)bis(2-amino-5-((aminoiminomethyl)amino)-, (2s,2's)-
11. Pentanamide, N,n'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2s,2's)-
12. Aripazine
13. (2s,2's)-n,n'-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide)
14. Unii-u2r67kv65q
15. Per 977
16. Ciraparantag [inn]
17. Ciraparantag [who-dd]
18. Chembl3544919
19. Schembl14985871
20. Dtxsid701045783
21. Cs-5640
22. Db15199
23. Hy-18660
24. D10868
25. Q27290602
26. (2s)-2-amino-n-[3-[4-[3-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propyl]piperazin-1-yl]propyl]-5-(diaminomethylideneamino)pentanamide
| Molecular Weight | 512.7 g/mol |
|---|---|
| Molecular Formula | C22H48N12O2 |
| XLogP3 | -4 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 18 |
| Exact Mass | 512.40231882 g/mol |
| Monoisotopic Mass | 512.40231882 g/mol |
| Topological Polar Surface Area | 246 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Brand Name: PER977
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Norgine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Norgine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
Details:
The published preclinical data demonstrate that ciraparantag has several key attributes including its ability to reverse the anticoagulant effect of apixaban, rivaroxaban, edoxaban, dabigatran, and LMWH.
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Brand Name: PER977
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The published preclinical data demonstrate that ciraparantag has several key attributes including its ability to reverse the anticoagulant effect of apixaban, rivaroxaban, edoxaban, dabigatran, and LMWH.
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2020
Details:
Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontrolled bleeding.
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Brand Name: PER977
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Norgine
Deal Size: $290.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement July 23, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Norgine
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontro...
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : $30.0 million
July 23, 2020
Details:
Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clotting time (WBCT).
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Brand Name: PER977
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clot...
Brand Name : PER977
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
